We review diagnostic and predictive roles of the angiogenic proteins placental growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in preeclampsia, and their association with future cardiovascular disease, diabetes and breast cancer. Specific patterns of these proteins represent preeclamptic prediction markers and combined with maternal and clinical characteristics, the predictive values increase. Women experiencing preeclampsia have increased risks of developing cardiovascular diseases and diabetes, and a decreased risk of breast cancer. High placental growth factor concentrations have in elderly patients been shown to predict cardiovascular events. Diabetes is also a risk factor for future cardiovascular disease. Diabetic vascular complications are associated with increased soluble endoglin concentrations, and vascular endothelial growth factor concentrations are correlated to HbA1c and fasting glucose. Thus dysregulation in angiogenic proteins may link preeclampsia and cardiovascular diseases, targeting women who could in future benefit from prophylactic programs topossibly prevent, delay or reduce cardiovascular disease.
Introduction
Preeclampsia and fetal growth restriction (FGR) are pregnancy complications associated with an increased risk for short-and long-term morbidity and mortality for both the mother and her offspring, such as adding to the risk for developing future cardiovascular disease (CVD) and diabetes mellitus (DM) (1;2). Simultaneously, women have a decreased risk of breast cancer development after preeclampsia (3) (4) (5) , although this is not confirmed in all epidemiological studies (6) .
The patophysiology of the preeclampsia syndrome is still elusive and not completely understood. The disease is, however, clinically and pragmatically usually defined as hypertension and proteinuria developing after 20 weeks of gestation (7) . Preeclampsia has often been subdivided into "placental" and "maternal" forms, stating unique patterns of pathogenesis and health issues both in the short and long term (8;9) .
[Skriv tekst] "Placental preeclampsia" is thought to arise from incomplete remodeling of the uteroplacental spiral arteries, presumably caused by dysregulated immunological interactions between fetal extravillous trophoblasts and maternal immune cells (10) leading to dysfunctional uteroplacental flow and excessive oxidative and endoplasmatic reticulum stress in the placenta (11) .
The dysfunctional placenta releases factors into the circulation causing a systemic inflammatory response (12) and generalized endothelial dysfunction mediating the clinical maternal signs of hypertension and proteinuria (13) . These placenta-generated factors include angiogenic proteins, and we have previously discussed their application in pregnancy as biomarkers of a dysfunctional placenta (14) .
"Maternal preeclampsia" is considered to develop in women with a normal placentation.
Predisposing factors associated with augmented inflammation such as obesity, DM and autoimmune diseases make the mother more susceptible to developing endothelial dysfunction, hypertension and proteinuria as a response to factors released from a normally functioning placenta (1) . "Placental preeclampsia", with incompletely remodeled uteroplacental spiral arteries, is thought to more often associated with early-onset disease and FGR, whereas the "maternal type" of preeclampsia, without apparent remodeling problems, is more often associated with late-onset disease, although a mix of both these not well-defined preeclampsia forms is probably the more common condition (14) .
The risk factors for developing preeclampsia seem also to segregate into the two subgroups of preeclampsia. Previous preeclampsia and nulliparity deviate towards the "placental" type, whereas obesity, high maternal age and diabetes, -much the same risk factors as for CVD, -predispose to the "maternal type" (15) . These clinical factors have, however, a limited predictive value in evaluating the risk for preeclampsia (16) . Likewise, pathological blood flow patterns in the uterine artery assessed by Doppler ultrasound, have limited value in the general screening for low-[Skriv tekst] risk pregnancies. Uterine artery blood flow as well as umbilical cord flow patterns are, however, widely used in the clinical setting to follow up high-risk patients with present or previous pregnancy complications associated with placental dysfunction (16) .
No cause-specific treatment for clinically established preeclampsia is available at present.
Delivery of the baby and thereby the placenta leads to amelioration of the clinical symptoms, paralleling a rapid decrease in the maternal circulating level of anti-angiogenic factors. Following a preeclamptic pregnancy, both the woman and her offspring are, however, at elevated risk for developing CVD (2;17-22) . The American Heart Association introduced in 2011 preeclampsia and FGR as risk factors for CVD (23) , but there is today no agreed follow-up protocol for CVD relating to pregnancy complications, partly due to an inability to identify the women at highest risk within these populations.
An improved subclassification of preeclampsia and FGR based on unique patterns of angiogenic biomarkers rather than on crude syndromic signs may provide useful in triaging women for follow-up, both during pregnancy and postpartum (14) . This might prove valuable for better timing of delivery in a pregnancy at risk for adverse maternal and offspring outcomes, and could be followed by potentially improved health outcomes for the mother and offspring (14) .
Several distinct circulating maternal angiogenic proteins appear to be present at abnormal levels in pregnant women with overt preeclampsia or growth restricted fetuses; furthermore, the relative and absolute concentrations of these proteins are altered prior to the clinical signs of these pregnancy complications (16;24) . This review summarizes the findings for the most assessed antiand pro-angiogenic circulating proteins in relation to pregnancy complications and their potential predictive roles hereto. In addition, a potential role of these circulating biomarkers in relation to future adult CVD, DM and breast cancer is discussed.
[Skriv tekst]

Material and methods
For the present review, a non-systematic PubMed search on was performed. Search words included "Preeclampsia/Intrauterine Growth Restriction/FGR/Small-for-Gestational Age/CVD/DM/Breast Cancer" in a combination with "Angiogenic factors/PlGF/sFlt/sEng/Prediction". Additional eligible studies were sought by hand search of reference lists from primary articles and reviews. We published a comprehensive review of potential preeclamptic plasma biomarkers in 2010 (16) , with a completed article search up to 
Results
Preeclampsia and future health risks
Several studies have shown increased risk of long-term cardiovascular complications such as coronary heart disease, tromboembolism, hypertension, stroke and CVD-associated death following [Skriv tekst] a history of preeclampsia or the delivery of a small-for-gestational age (SGA) infant (10;17-19;25-31) . The risk is highest among women who develop both preeclampsia and FGR (28) , for those with early-onset preeclampsia (17;18;25;31) , repeated preeclampsia (28) or severe preeclampsia (18) . The relative risk after preeclampsia for developing CVD varies from 1.3 to 3.3, with a higher risk range of 2.7-8.1 in more severe preeclampsia (32) , implying a "dose-response" relation between severity of preeclampsia and future CVD. FGR implies failure to realize a genetically determined growth potential and many FGR fetuses, but not all, will also be SGA. Not all SGA fetuses are FGR, they are just constitutionally small. The fetal growth terminology is controversial and inconsistent among obstetricians; however, the most widely used definition of SGA is fetal weight below the 10 th percentile (33) .
Cardiovascular risk factors present before a hypertensive pregnancy could be important determinants of subsequent long-term cardiovascular risk after a preeclamptic pregnancy, but this does not exclude that the pregnancy by itself, and a pregnancy complication with poor placental function like the "placental" type of preeclampsia in particular (8;9), could also contribute to the augmented risk for later cardiovascular disease.
DM and preeclampsia share many pathophysiological features, such as inflammation, oxidative stress, insulin resistance and endothelial dysfunction (34;35) . Both pre-gestational and gestational diabetes (GDM) are associated with an increased risk of developing preeclampsia (36) (37) (38) (40), places women at increased risk of DM later in life, in line with previous publications demonstrating increased risk of type II DM after preeclampsia (41) , even in patients without co-existing GDM (42) . Insulin resistance is a feature of normal pregnancy which is exaggerated in preeclampsia and even more so in GDM, and it may represent a link between these pregnancy complications and future DM and CVD (43;44) .
[Skriv tekst]
In contrast to an augmented risk of diseases such as CVD and DM following preeclampsia, women with a history of preeclampsia or gestational hypertension have a reduced breast cancer risk compared to women who have had only uncomplicated pregnancies (45;46) . An even larger reduction is seen with elevated mean arterial pressures (47) and systolic blood pressures from midto late pregnancy, but below the diagnostic levels for preeclampsia (48) . This inverse correlation between breast cancer and a history of preeclampsia is, however, not consistent (49) . The mechanisms are at present unknown, but might be related to tumor vascularization and growth, and possibly to remote effects of dysregulated local or circulating angiogenic factors during pregnancy.
Angiogenic factors and preeclampsia
Preeclampsia is characterized by a maternal circulating anti-angiogenic profile, with elevated anti-angiogenic proteins, and decreased pro-angiogenic proteins (reviewed in (16)). This pattern is also seen prior to clinical signs of preeclampsia, and in animal models, these proteins participate in processes that induce preeclampsia-like disorders (50-53).
In normal pregnancies, the pro-angiogenic protein placental growth factor (PlGF) peaks at 30 weeks (54) and decreases towards term (55;56). It is involved in angiogenesis and vasculogenesis, which are important processes in embryogenesis (57) shown that in women presenting with suspected preeclampsia before 35 weeks' gestation, low PlGF had a higher sensitivity and negative predictive value for preeclampsia within 14 days (79).
As opposed to PlGF, the maternal concentrations of the "anti-angiogenic protein" soluble fms-like tyrosine kinase-1 (sFlt1) remain stable during the first two trimesters of a normal pregnancy, and thereafter increase towards term (56;80). The action of sFlt1 and its interaction with the "pro-angiogenic proteins" vascular endothelial growth factor (VEGF) and PlGF during pregnancy is complex (14) . It is believed that sFlt1 acts as a "decoy protein" in pregnancy, reducing free concentrations of VEGF and PlGF, thereby reducing the vasodilation effect on the endothelium, thus at the same time inducing vasoconstriction and contributing to the development of hypertension and proteinuria (58). An increased concentration of sFlt1 in the maternal circulation has been shown in preeclamptic patients (9) , both in second and third trimester (52;60-62;81-84).
The associations are, similarly as for PlGF, stronger in early-onset (60;61;81) and severe preeclampsia (52), however, not all studies agree hereto (62;85). Elevated sFlt1 concentrations in pregnancy have also been associated with smaller head and chest circumferences and with
birthweight (86) , as well as being positively correlated to mean arterial pressure and proteinuria (58;84), although there are some discrepant conclusions (62).
As for predicting preeclampsia, low sFlt1 concentrations in the first trimester appear to predict early-onset preeclampsia in some studies (67;72) , and a high sFlt1 increase from the first to the second trimester may entail an augmented risk of preeclampsia (72) . Results from the latter cohort recently showed that low sFlt1 in the first trimester could predict early-onset preeclampsia independently of SGA, and also late-onset preeclampsia together with SGA (69 
Angiogenic factors in relation to small-for-gestational age and fetal growth restriction
FGR has also been associated with a dysregulated maternal angiogenic profile (16 
Angiogenic factors in relation to cardiovascular disease
It has been proposed that women with acute atherosis of the uteroplacental spiral arteries, a feature of many pregnancies complicated by preeclampsia, could be at excessive risk for premature atherosclerosis and CVD development (10) . These acute atherosis lesions are histological changes resembling early stages of histological atherosclerosis (108), and we have suggested that these lesions could represent an accelerated form of early atherosclerosis developed during the short time of pregnancy (1).
Another similarity between atherosclerosis and acute atherosis is the inflammatory component (108) . PlGF is shown to be up-regulated in atherosclerotic lesions of patients with acute coronary syndrome, where it is believed to act as an inflammatory instigator of atherosclerotic plaque instability (109) , and elevated circulating PlGF could indicate a risk for higher mortality and disease events in patients with coronary heart disease. Also, in these elderly individuals, circulating PlGF levels were positively correlated with levels of the inflammation marker CRP (109;110). It is suggested that the source of the elevated PlGF in the circulation of these patients is the inflamed endothelium. There is in contrast a low circulating concentration of PlGF during and prior to preeclampsia development, probably secondary to placental dysfunction and the binding of free and vascular-active PlGF as well as VEGF by the elevated amount of placenta-freed sFlt1 (52).
Angiogenic factors in relation to diabetes mellitus
Angiogenic factors have also been investigated in order to improve the understanding of the pathogenesis and vascular complications in DM. It has been shown that elevated circulating sEng is correlated to microangiopathy, hypertension, increased disease duration, besides a family history of diabetes type 2 (111). Circulating VEGF is positively correlated to Hba1c and fasting glucose (112) .
It is important to underline that the latter pattern is the opposite of what is observed in preeclampsia,
where it is plausible that the effect of placenta dysfunction overrides the vascular dysfunction for the circulating biomarkers that are measured in pregnancy. The common denominator is the inflamed endothelium, which in the case of preeclampsia is secondary to the placenta-mediated generalized (and vascular) inflammation (12) . The complex patterns of pathogenesis in the two situations could then determine the outcome for the woman.
Angiogenic factors and cancer
The mechanisms mediating breast cancer protection after a case of gestational hypertension are unknown. We have speculated that the anti-angiogenic state implying negative growth conditions for tumor growth and metastasis plays a role in the association between a dysfunctional placenta and future reduced malignant tumor development (113) . The circulating anti-angiogenic sFlt/VEGF ratio in a woman with breast cancer is inversely associated with tumor size, and it is significantly lower in breast cancer patients than controls (114) . Augmented concentrations of circulating PlGF in a woman with breast cancer have been suggested to be a positive predictor of breast cancer recurrence, metastasis and patient mortality, and to be associated with its angiogenic properties (115) . However, there is currently no documentation of any relation between dysregulated angiogenic responses during pregnancy and later breast cancer development, although a possible correlation cannot be excluded.
Discussion
The circulating maternal concentrations of the angiogenic biomarkers in pregnancy are a net result of many complex processes (1) . The study of their association to preeclampsia, cardiovascular disease, diabetes mellitus and breast cancer may generate new insights to the pathophysiology of these diseases and suggest mechanisms for their pathophysiological interaction.
A high release of anti-angiogenic factors such as sFlt1 from a dysfunctional placenta is proposed to have a negative impact on the maternal endothelium by neutralizing beneficial VEGF and PlGF in the circulation (52), but the direct relation of this to future vascular disease is unknown. Due to their relation to preeclampsia, and also to the epidemiological association between preeclampsia, DM and CVD, we speculate that these biomarkers may be useful in risk-selection of women for postpartum intervention trials aimed at reducing the risk for, or the severity of, these later-life diseases.
The demonstrated role of PlGF in enhancing blood flow and contractile function of ischemic myocardium underlines its role in vascular homeostasis, and provides room for a hypothesis of an indirect interplay between preeclampsia and CVD (116) . If PlGF improves myocardial function, and its levels decrease during preeclampisa, it is possible that the low PlGF state of preeclampsia can contribute as a factor increasing the risk of CVD through long-term effects on cardiac function.
sEng, released in excess from a dysfunctional placenta, may have negative effects on vascular tone (51), possibly also adding to the factors that may mediate a relation between preeclampsia, CVD and DM. A genetical link between CVD and preeclampsia is also under investigation, and recent research by our group has demonstrated a G-protein phenotype, which plays a role in blood pressure regulation, which also affects the risk for and progression of preeclampsia (117).
As for breast cancer, an anti-angiogenic state opposes tumor development (118) . We propose that a woman's general angiogenic response disposition, whether in pregnancy or if challenged by breast tumor growth, might represent a link between the anti-angiogenic state in pregnancy and a later beneficial low tumor growth situation in the same woman.
At present, longitudinal studies after a preeclamptic pregnancy point in different directions regarding long-term angiogenic dysregulation. Some studies show no difference in the concentrations of circulating PlGF and sFlt1, measured both one (119) and ten (120) years postpartum between women with previous preeclampsia and control individuals. The same is seen for sEng one year post-partum (119) . One study showed that circulating sFlt1 levels are raised 18 months after preeclampsia (121) . We also found higher median circulating sFlt1 in women with previous preeclampsia complicated by SGA in our own long-term follow-up study (5-8 years after preeclampsia), together with evidence of maternal and child endothelial dysfunction (122) . In several studies increased arterial stiffness after preeclampsia has been shown (119;123;124).
As circulating PlGF has opposite patterns in CVD and preeclampsia, with augmented levels in the former and very low levels in the latter, there is no intuitive logical link between these two syndromes with abnormal PlGF situations. Circulating PlGF is elevated in older persons with a high risk of a future CVD event, where circulating PlGF stems from excessive vascular inflammation. In contrast, low PlGF in pregnancy (probably mostly due to binding of free PlGF to excessive sFlt1 secondary to a dysfunctional placenta) appears predictive of preeclampsia and fetal growth restriction. At present we do not know whether a dysregulated angiogenic factor situation in pregnancy is just a marker of the future health risk for the women, possibly reflecting a common genetic risk for preeclampsia and future cardiovascular disease. The other alternative is that dysregulated angiogenic factors in pregnancy could also mediate future health problems, for
example by directly or indirectly affecting vascular health. The first alternative does not exclude the latter.
An interesting link between CVD and preeclampsia is that both have foam cell deposition in arteries, as preeclampsia often is complicated by uteroplacental acute atherosis (10) . We are at present studying whether there is a link between these vascular inflammatory changes in CVD and preeclampsia and are using a decidual vacuum suction method that is optimal for collecting relevant uteroplacental tissue to study inflammatory lesions of these uteroplacental arteries (125) .
As women with a history of hypertensive disorders in pregnancy have an increased risk for developing future diabetes mellitus (36-38;42) ), a prevention program and follow-up would be desirable, but this is not the clinical practice world-wide. GDM is a strong risk factor for future diabetes, and women with GDM are today in many countries recommended to undergo postpartum DM screening (43) . According to the annual report of the Norwegian Medical Birth Register (126), more women experience gestational hypertension and preeclampsia than GDM. We therefore believe that the group of women who have experienced gestational hypertension or preeclampsia are important candidates for DM (127) as well as for CVD follow-up programs, in order to prevent or enable early diagnosis and treatment of these diseases.
Current available tests for the circulating angiogenic factors sFlt1, sEng and PlGF have too low sensitivity and specificity to be used singularly as a screening tool for preeclampsia in low-risk pregnancies, although the use of PlGF in women with suspected preeclampsia after week 35 is promising. No cost-benefit analyses have hitherto been published comparing these biomarkers or their combinations, but among the single biomarkers, PlGF seems today to be the better predictor for preeclampsia (128) .
Cnossen argues that when it comes to the questions of specificity and sensitivity in screening for preeclampsia, high sensitivity is preferable, if one has to choose (129) . Preeclampsia
is a disease that can result in maternal and fetal death, and low sensitivity is therefore absolutely unfavorable. On the other hand, low specificity will lead to unnecessary use of health resources and cause unnecessary concern and burden for healthy pregnant women. Future studies must bear in mind that the ultimate goal of the research on preeclampsia-related biomarkers is not to predict and reduce the incidence of preeclampsia, but to improve maternal and child health, both in the short and in the long run. If we can document a relation (even if there would be no mechanistic associations) between dysregulated angiogenic factors in pregnancy (most likely due to placental dysfunction) and an augmented risk for future CVD, targeted intervention studies for women at highest risk could be undertaken in order to prevent, postpone or reduce the severity of CVD. The several decades (22) that may lie between a pregnancy with a dysfunctional placenta and the first clinical signs of CVD represent a large "window of opportunity" for intervention programs in women at highest risk, with potentially reduced health cost for the woman, her family and society and for enhancing quality of life.
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